P

    Prelude Therapeutics Inc (PRLD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.60
    +0.13 (+2.38%)

    Market Cap: $435.66M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(17/25)
    Avg Surprise
    -47.68%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.17
    Range$-0.18 - $-0.16
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.25-47.1%
    60d ago$-0.24-41.2%
    30d ago$-0.24-41.2%
    7d ago$-0.22-29.4%
    Current$-0.17
    Revenue Consensus
    $33M
    Range$0 - $100M
    3 analysts
    Dec 31, 2026
    EPS Consensus$0.08
    Range$0.08 - $0.08
    1 analysts
    Revenue Consensus
    $33M
    Range$-11370330 - $77M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.08---
    Sep 26EST
    		-$-0.17---
    Jun 26
    		$-0.14$-0.17+17.65%Beat+65.9%
    Mar 26
    		$-0.13N/A+51.85%Beat+69.0%
    Dec 25
    		$-0.20$-0.13-53.85%Miss+45.9%
    Sep 25
    		$-0.26$-0.35+25.71%Beat+39.5%
    Jun 25
    		$-0.41$-0.43+4.65%Beat+10.9%
    Mar 25
    		$-0.42$-0.46+8.70%Beat+0.0%
    Dec 24
    		$-0.37$-0.47+20.82%Beat+17.8%
    Sep 24
    		$-0.43$-0.46+6.52%Beat+4.4%
    Jun 24
    		$-0.46$-0.43-6.98%Miss+14.8%
    Mar 24
    		$-0.42$-0.48+12.50%Beat+27.6%
    Dec 23
    		$-0.45$-0.49+8.16%Beat+25.0%
    Sep 23
    		$-0.45$-0.58+22.41%Beat+28.6%
    Jun 23
    		$-0.54$-0.63+14.29%Beat+6.9%
    Mar 23
    		$-0.58$-0.70+17.14%Beat+7.9%
    Dec 22
    		$-0.60$-0.63+4.76%Beat+15.5%
    Sep 22
    		$-0.63$-0.64+1.56%Beat+4.5%
    Jun 22
    		$-0.58$-0.63+7.94%Beat+0.0%
    Mar 22
    		$-0.63$-0.65+3.08%Beat-34.0%
    Dec 21
    		$-0.71$-0.68-4.41%Miss-57.8%
    Sep 21
    		$-0.66$-0.62-6.45%Miss-73.7%
    Jun 21
    		$-0.58$-0.49-18.37%Miss+89.5%
    Mar 21
    		$-0.47$-0.42-11.90%Miss-
    Dec 20
    		$-0.45$-0.47+4.26%Beat-
    Sep 20
    		$-0.38$-0.34-11.76%Miss-
    Jun 20
    		$-5.50$-0.39-1310.26%Miss-

    Key Metrics

    Valuation
    P/E Ratio-7.67EV/EBITDA-0.54x
    Price/FCF-16.57xFCF Yield-6.04%
    Profitability
    Profit Margin-269.70%Operating Margin-270.90%
    ROE-57.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.07xQuick Ratio4.07x
    Trading Statistics
    Beta0.94Avg Volume527.62K
    52-Week High$6.8352-Week Low$0.98

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.17
    SMA 20$5.64
    SMA 50$4.96
    SMA 200$3.54
    EMA 10$5.96
    EMA 20$5.69
    EMA 50$5.13
    EMA 200$3.77

    MACD

    Line: 0.38Signal: 0.43Hist: -0.05

    ADX

    ADX: 31.7+DI: 22.4-DI: 23.9

    Aroon & PSAR

    Aroon Up80.0
    Aroon DownN/A
    PSAR$6.76

    Bollinger Bands

    Upper Band$7.05
    Lower Band$4.22
    %B Position5016%(Upper)
    Band Width0.49

    RSI (14-Day)

    Neutral
    51.4

    Momentum Oscillators

    Stoch %K44.8
    Stoch %D64.8
    Williams %R-73.2
    ROC (10d)-0.5%
    Momentum-0.03
    CCI (20d)-16.2
    MFI (14d)61.3

    Volatility Measures

    ATR (14d)$0.48(8.5%)
    StdDev (20d)0.71
    Hist Vol89.4%(High)

    Volume Flow

    VWAP$5.49
    OBV19.6M
    AD Line21.6M
    CMF (20d)0.208

    Volume Metrics

    Avg Vol (20d)539.6K
    Vol Ratio1.3x
    VWMA (20d)$5.89

    Pivot Points

    R3$7.05
    R2$6.72
    R1$6.09
    Pivot Point$5.76
    S1$5.13
    S2$4.80
    S3$4.17

    Advanced Oscillators

    TSI25.15
    Ultimate Osc48.6
    KST330.00

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.70M$4.58M$5.64M$6.50M$0$0$4.00M$3.00M$0$0$3.42M$0
    Cost of Revenue$0$0$418,000$0$0$0$489,000$0$0$0$331,000$0
    Gross Profit$5.70M$4.58M$5.64M$6.50M$0$0$4.00M$3.00M$0$0$-331,000$0
    Operating Expenses$21.16M$18.76M$22.99M$26.92M$32.19M$34.61M$37.83M$37.38M$37.16M$34.34M$37.38M$33.38M
    R&D$16.13M$13.60M$17.99M$21.71M$25.78M$28.82M$31.62M$29.46M$29.51M$27.41M$30.33M$26.26M
    SG&A$5.03M$5.16M$5.00M$5.21M$6.41M$5.79M$6.21M$7.92M$7.66M$6.93M$7.05M$7.12M
    Operating Income$-15,454,000$-14,177,000$-17,348,000$-20,418,000$-32,194,000$-34,606,000$-33,831,000$-34,376,000$-37,164,000$-34,343,000$-37,379,000$-33,385,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$6.14M$0
    Income Before Tax$-13,921,000$-10,385,000$-16,457,000$-19,725,000$-31,231,000$-32,085,000$-28,731,000$-32,271,000$-34,740,000$-31,431,000$-43,520,000$-30,608,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-13,921,000$-10,385,000$-16,457,000$-19,725,000$-31,231,000$-32,085,000$-28,731,000$-32,271,000$-34,740,000$-31,431,000$-33,075,000$-30,608,000
    EBITDA$-13,881,000$-10,382,000$-16,227,000$-19,349,000$-31,011,000$-31,571,000$-29,193,000$-32,681,000$-35,620,000$-32,546,000$-38,119,000$-31,926,000
    EBIT$-13,921,000$-10,385,000$-16,457,000$-19,725,000$-31,231,000$-32,085,000$-28,731,000$-32,271,000$-34,740,000$-31,431,000$-37,379,000$-30,608,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRLD

    News

    Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

    Wall Street analysts project a potential upside of 33.6% for Prelude Therapeutics (PRLD), with an average price target of $6.88. Despite the consensus, the article cautions against relying solely on price targets, highlighting that analyst predictions can often be overly optimistic due to business incentives. However, strong agreement among analysts on higher earnings estimates and a Zacks Rank #2 (Buy) suggest a legitimate reason for optimism regarding PRLD's stock performance.

    qz.com•8/26/26•
    Bullish

    Price to earnings forward of Prelude Therapeutics Incorporated – NASDAQ:PRLD

    This article provides the "Price to earnings forward" value for Prelude Therapeutics Incorporated (NASDAQ: PRLD). It presents the financial data under a "Period Value Change" format. The data is made available through TradingView, with market data provided by ICE Data Services and reference data by FactSet.

    TradingView•8/22/26•
    Neutral

    Prelude Therapeutics (NASDAQ:PRLD) Reaches New 1-Year High - Still a Buy?

    Prelude Therapeutics (NASDAQ:PRLD) recently hit a new 52-week high of $6.65, closing at $6.50, an increase of 12.5% from its previous close. Despite this, analyst sentiment is mixed, resulting in a consensus "Hold" rating with an average price target of $7.67. The company surpassed earnings expectations with a quarterly loss of $0.14 per share against an estimated $0.20 loss, and institutional investors hold a significant 79.72% of the stock.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Prelude Therapeutics (NASDAQ:PRLD) Shares Up 9.3% - Time to Buy?

    Prelude Therapeutics (NASDAQ:PRLD) saw its shares increase by 9.3% to $6.32, despite trading volume being 20% below average. The company exceeded quarterly earnings expectations, reporting a loss of $0.14 per share against a projected $0.20 loss, with revenue matching estimates at $5.7 million. While analyst ratings are mixed, with a consensus "Hold" and an average price target of $7.67, institutional investors and hedge funds hold a significant 79.72% of the stock.

    MarketBeat•8/20/26•
    Somewhat-Bullish

    Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear

    Prelude Therapeutics (PRLD) saw its stock rally by 10.1% despite still reporting research-stage losses in Q2 2026, driven by a significant narrowing of its net loss and the initiation of modest revenue. While the financial picture appears cleaner due to collaborations, the market is still awaiting clear updates on key clinical milestones for its drug candidates, which remain a point of concern for investors. The article highlights the importance of these clinical advancements for the company's long-term bullish narrative, suggesting that without them, the stock's rally might be precarious.

    Sahm•8/12/26•
    Somewhat-Bullish

    Frequently Asked Questions About PRLD

    Does PRLD pay dividends?
    Prelude Therapeutics Inc (PRLD) does not currently pay a regular dividend.
    What is PRLD's market cap?
    Prelude Therapeutics Inc (PRLD) has a market capitalization of $435.66M with a current stock price of $5.60.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In